Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1643 1647
This examiner grants 81% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18535068 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | Non-Final OA | AMGEN INC. |
| 18489525 | METHODS FOR PREVENTING AND TREATING HEART DISEASE | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 18583340 | Compositions and Methods for Targeting Connexin Hemichannels | Non-Final OA | Board of Regents, The University of Texas System |
| 18043534 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | Non-Final OA | YALE UNIVERSITY |
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | Non-Final OA | St. Jude Children's Research Hospital, Inc. |
| 18480730 | ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18023246 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF DIALYSIS PRURITUS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18031940 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18543912 | PSGL-1 Antagonists and Uses Thereof | Non-Final OA | Five Prime Therapeutics, Inc. |
| 17997241 | MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS | Non-Final OA | TENEOBIO, INC |
| 18034177 | CHIMERIC ANTIGEN RECEPTOR TARGETING CD7 AND USE THEREOF | Non-Final OA | BIOHENG THERAPEUTICS LIMITED |
| 17928427 | Methods and Treatment Involving Antibodies to IL-18 | Final Rejection | Avalo Therapeutics, Inc. |
| 17999786 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18030203 | MEDICINE FOR TREATING CANCER | Non-Final OA | CHIOME BIOSCIENCE INC. |
| 18245691 | SINGLE-DOMAIN ANTIBODY TARGETING 4-1BB, FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | BIOTHEUS INC. |
| 18043570 | ANTIBODIES SPECIFIC TO CCL21 AND METHODS OF USE | Non-Final OA | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18021568 | ANTI-FACTOR XII (FXII) NANOBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOF | Non-Final OA | NINGBO COMGEN BIOTECH CO., LTD. |
| 18005752 | FUSION PROTEIN COMPRISING IGE FC RECEPTOR ALPHA SUBUNIT EXTRACELLULAR DOMAIN AND ANTI-IL-4R ANTIBODY, AND USE THEREOF | Non-Final OA | GI INNOVATION, INC. |
| 17765009 | CH1 DOMAIN VARIANTS ENGINEERED FOR PREFERENTIAL LIGHT CHAIN PAIRING AND MULTISPECIFIC ANTIBODIES COMPRISING THE SAME | Non-Final OA | ADIMAB, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy